INTU Diagnostics
INTU Diagnostics develops PCR-TO-GO, an instrument-free molecular diagnostic platform that detects pathogens' genetic material with lab-level accuracy without requiring electricity, equipment, or specialized training. The self-contained test kit uses a simple three-step workflow—sample collection, cartridge placement, and result reading—making it suitable for at-home use and low-resource settings. The technology has been validated in field testing for Chlamydia trachomatis in Tanzania, with tests expected to be available starting in 2027.
- Healthcare Technology
- Medical Devices
- Biotechnology
- Hardware
Funding
Founders
Founder details are not available yet.
Product
Problem
Molecular diagnostic tests such as PCR are highly accurate but typically require laboratory infrastructure, specialized equipment, and trained personnel, making them inaccessible in low-resource settings and inconvenient for at-home use. Patients in remote or underserved areas face delayed diagnoses and missed infections, particularly for infectious diseases where timely detection is critical.
Solution
INTU Diagnostics provides instrument-free molecular diagnostic tests that detect pathogens' genetic material with accuracy comparable to lab-based PCR tests. The PCR-TO-GO platform requires no electricity, equipment, or specialized training—users simply collect a sample, place it in a self-contained cartridge, and read the results. The technology has been validated in real-world field testing in Tanzania for Chlamydia trachomatis, demonstrating reliable performance under non-ideal conditions. The company is also developing an infrastructure-free molecular diagnostic platform for cervical cancer screening through the MIRA project, enabling accurate HPV detection without power or laboratory access. Tests will be available starting in 2027, with a signup option for launch notifications.
Target Audience
Primary customers include individuals seeking at-home infectious disease testing, healthcare providers in low-resource settings, and public health organizations focused on cervical cancer screening and infectious disease control in underserved regions.
Features
- Instrument-free molecular detection of pathogen genetic material, achieving lab-PCR-level accuracy without equipment
- Self-contained test kit with integrated cartridge that requires no electricity or additional supplies
- Three-step workflow: sample collection, cartridge placement, and result reading
- Validated performance in resource-limited field settings through a Chlamydia trachomatis feasibility study in Tanzania
- Platform technology adaptable to multiple infectious disease targets, including HPV for cervical cancer screening
- Designed for affordability and usability in at-home and low-resource environments